Document 0870
 DOCN  M9550870
 TI    Clinical aspects of human immunodeficiency virus disease: clinical
       rationale for treatment.
 DT    9505
 AU    Murphy R; Division of Infectious Diseases, Northwestern University
       School; of Medicine, Chicago, Illinois.
 SO    J Infect Dis. 1995 Mar;171 Suppl 2:S81-7. Unique Identifier : AIDSLINE
       MED/95164993
 AB    Guidelines regarding the use of antiretroviral therapy in adult patients
       infected with human immunodeficiency virus have been based primarily on
       the results of 15 major clinical trials in which patients have been
       categorized according to CD4 cell counts, symptoms, prior therapy, and
       conditions. In patients with limited treatment experience and advanced
       disease, zidovudine monotherapy is associated with improved survival,
       whereas only a transient delay in progression of disease is observed in
       patients with > 200 CD4 cells/mm3. Adding zalcitabine to the treatment
       regimen of zidovudine-experienced patients with advanced disease has not
       been demonstrated to be of clinical benefit, whereas switching these
       patients to didanosine may delay disease progression. The effect of any
       antiretroviral therapy in zidovudine-experienced patients with < 50 CD4
       cells/mm3 remains indeterminate. The perinatal transmission rate can be
       reduced by as much as two-thirds when zidovudine is administered to
       women after the first trimester.
 DE    Clinical Trials  CD4 Lymphocyte Count  Dideoxynucleosides/*THERAPEUTIC
       USE  Female  Human  HIV Infections/*DRUG THERAPY/IMMUNOLOGY  Male
       Pregnancy  Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).